7 completed. 7 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 7 | Completed 7 |
| Phase 2 | 3 | Completed 3 |
Follow vosaroxin: new trials by email Literature Review of vosaroxin trials Research Report on vosaroxin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Vosaroxin and Azacitidine in Treating Patients With Myelodysplastic Syndromes vosaroxin, Azacitidine - Myelodysplastic Syndromes | Phase 1 | Completed | Washington University School of Medicine | 35 | 2013-11-22 | 2024-05-02 |
| Vosaroxin for Intermediate 2 or High-risk MDS After Failure With Hypomethylating Agent-based Therapy Vosaroxin - Myelodysplastic Syndrome | Phase 1 / Phase 2 | Completed | Weill Medical College of Cornell University | 10 | 2013-10-25 | 2019-02-19 |
| Study of Vosaroxin and Decitabine in Older Patients With Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome Vosaroxin, Decitabine - Leukemia | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 66 | 2013-07-18 | 2022-02-09 |
| Safety and Tolerability Study of Voreloxin and Cytarabine Combination in Acute Myeloid Leukemia in Humans Voreloxin injection and cytarabine - Acute Myeloid Leukemia | Phase 1 / Phase 2 | Completed | Sunesis Pharmaceuticals | 110 | 2007-10-06 | 2018-01-09 |
| Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies Vosaroxin - Leukemia, Lymphocytic, Acute, Leukemia, Nonlymphocytic, Acute | Phase 1 | Completed | Sunesis Pharmaceuticals | 75 | 2005-11-14 | 2017-03-30 |
| Safety Assessment of Weekly Intravenous Infusions of SNS-595 for the Treatment of Solid Tumors SNS-595 - Neoplasms | Phase 1 | Completed | Sunesis Pharmaceuticals | 2004-10-01 | 2007-05-10 | |
| Initial Safety Assessment of SNS-595 for the Treatment of Solid Tumors. SNS-595 - Neoplasms | Phase 1 | Completed | Sunesis Pharmaceuticals | 2004-06-01 | 2007-05-10 |
Neoplasms (4) · Leukemia (3) · Leukemia, Myeloid, Acute (3) · Myelodysplastic Syndromes (3) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (1) · Leukemia, Myelomonocytic, Chronic (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Recurrence (1)
Sunesis Pharmaceuticals (4) · M.D. Anderson Cancer Center (1) · Washington University School of Medicine (1) · Weill Medical College of Cornell University (1)
United States (7)
Daniel C. Adelman, MD (2) · Gail Roboz, MD (1) · Glenn Michelson, MD (1) · Meagan Jacoby, M.D., Ph.D. (1) · Naval Daver, MD (1)